Skip to main content
. 2022 Dec 21;28(47):6743–6751. doi: 10.3748/wjg.v28.i47.6743

Figure 1.

Figure 1

Number of therapeutic trials described in studies including 2 or more inflammatory bowel disease patients. TNFi: Tumor necrosis factor inhibitor; TOF: Tofacitinib; UST: Ustekinumab; VDZ: Vedolizumab.